quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 13, 2025

Disney targets double-digit EPS growth and $7B share repurchases in 2026 as direct-to-consumer and Experiences segments accelerate

View original at seekingalpha.com
Disney targets double-digit EPS growth and $7B share repurchases in 2026 as direct-to-consumer and Experiences segments accelerate Earnings Call Insights: The Walt Disney Company (DIS) Q4 2025 MANAGEMENT VIEW * CEO Robert Iger stated, "This was another year of great progress as we strengthened the company by leveraging…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Disney is targeting $7 billion in share repurchases in 2026, double the $3.5 billion repurchased in fiscal 2025

    80% confidence
  • Disney has aspirations for double-digit top-line growth in direct-to-consumer

    80% confidence
  • Disney is very bullish on the upcoming slate including The Mandalorian, Toy Story 5, live-action Moana and Avengers: Doomsday

    80% confidence
  • Disney expects advertising growth in 2026 with improving advertising trends

    80% confidence
  • Disney's priority is to remain on YouTube TV's service without interruption, and the proposed deal is equal to or better than what other large distributors have agreed to

    80% confidence
  • Disney expects continued strong free cash flow growth going forward, giving flexibility to return cash to shareholders

    80% confidence
  • Disney's live-action Lilo & Stitch remains the highest grossing Hollywood film at the global box office this calendar year

    80% confidence
  • About 80% of ESPN direct-to-consumer users have signed up for the trio bundle, which includes Disney+ and Hulu

    80% confidence
  • Disney's streaming business had operating income up 39% in Q4, hitting $1.3 billion for the full year, up $1.2 billion from last year and $300 million ahead of original guidance

    80% confidence
  • Disney expects to deliver double-digit adjusted EPS growth in fiscal 2026 compared to the prior year

    80% confidence
  • Disney has no plans for major M&A and is satisfied with current IP portfolio

    80% confidence
  • Retail sales for Stitch from Disney's Consumer Products business exceeded $4 billion in fiscal 2025

    80% confidence
  • Disney built a hedge into financials with expectation that YouTube TV discussions could go for a while

    80% confidence
  • Adjusted EPS for fiscal 2025 was up 19% from fiscal 2024, and the company delivered a 19% compound annual growth rate in adjusted EPS over the past three fiscal years

    80% confidence
  • Cruise utilization is strong and margins are attractive but not disclosed

    80% confidence
  • Over the past 2 years, Disney's studios have delivered 4 global franchise hits that have earned more than $1 billion each, while no other Hollywood studio has achieved a single one during the same period

    80% confidence
  • Lilo & Stitch achieved 14.3 million views during its first 5 days on Disney+, becoming the second biggest Disney live-action premiere on the platform ever

    80% confidence
  • Disney is having productive conversations with AI companies for both protection of IP and creating engagement, and sees efficiency opportunities across Disney

    80% confidence
  • Cruise is a key growth driver for Disney Experiences, with bookings up 3% for the first quarter and for the year

    80% confidence

Data points we hold from this source

The Walt Disney Company · direct to consumer operating income growth1.2 billion_USD
The Walt Disney Company · direct to consumer operating income1.3 billion_USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Disney targets double-digit EPS growth and $7B share repurchases in 2026 as direct-to-consumer and Experiences segments accelerate — Source | Via News | pt.VIA.NEWS